We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes
Why needed?
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
Our solution
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
Bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans are rapidly being developed. It is anticipated that some applications will be ready for
The VANGUARD consortium recently published collaborative work in the journal Transplant International on the generation of pre-vascularised organoids. The authors from the University of Geneva
Online workshop on the topic of bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans that are rapidly being developed.